News Focus
News Focus
icon url

DewDiligence

10/08/13 8:52 PM

#167788 RE: DewDiligence #167117

RGDO’s REGULATE-PCI study is one of the highest-risk phase-3 trials I’ve ever seen conducted by a small biotech company without a partner. The cost of running the trial is $150M, according to today’s webcast.

Clinicaltrials.gov listing: http://www.clinicaltrials.gov/ct2/show/NCT01848106 .